- Home
- ARMP vs CEE Comparison
ARMP vs CEE Comparison
Compare ARMP & CEE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARMP
- CEE
- Stock Information
- Founded
- ARMP N/A
- CEE 1990
- Country
- ARMP United States
- CEE Germany
- Employees
- ARMP N/A
- CEE N/A
- Industry
- ARMP Biotechnology: Biological Products (No Diagnostic Substances)
- CEE Finance Companies
- Sector
- ARMP Health Care
- CEE Finance
- Exchange
- ARMP Nasdaq
- CEE Nasdaq
- Market Cap
- ARMP 125.7M
- CEE 101.1M
- IPO Year
- ARMP N/A
- CEE N/A
- Fundamental
- Price
- ARMP $5.73
- CEE $15.62
- Analyst Decision
- ARMP Strong Buy
- CEE
- Analyst Count
- ARMP 1
- CEE 0
- Target Price
- ARMP $9.00
- CEE N/A
- AVG Volume (30 Days)
- ARMP 759.0K
- CEE 22.0K
- Earning Date
- ARMP 11-07-2025
- CEE 01-01-0001
- Dividend Yield
- ARMP N/A
- CEE 3.86%
- EPS Growth
- ARMP N/A
- CEE N/A
- EPS
- ARMP N/A
- CEE N/A
- Revenue
- ARMP $6,868,000.00
- CEE N/A
- Revenue This Year
- ARMP $8.43
- CEE N/A
- Revenue Next Year
- ARMP N/A
- CEE N/A
- P/E Ratio
- ARMP N/A
- CEE N/A
- Revenue Growth
- ARMP 84.67
- CEE N/A
- 52 Week Low
- ARMP $0.90
- CEE $7.80
- 52 Week High
- ARMP $16.34
- CEE $10.32
- Technical
- Relative Strength Index (RSI)
- ARMP 63.43
- CEE 50.82
- Support Level
- ARMP $4.65
- CEE $15.17
- Resistance Level
- ARMP $6.36
- CEE $15.78
- Average True Range (ATR)
- ARMP 1.34
- CEE 0.37
- MACD
- ARMP 0.01
- CEE 0.01
- Stochastic Oscillator
- ARMP 22.25
- CEE 61.11
About ARMP Armata Pharmaceuticals Inc.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
About CEE The Central and Eastern Europe Fund Inc. (The)
CENTRAL & EASTERN EUROPE FUND, INC. is a closed-end management investment company. The Fund's objective is to seek long-term capital appreciation. It invests in the equity or equity-linked securities of issuers domiciled in Central and Eastern Europe.